EIT Pharma: Funding, Investors & Team (Sep 2026)
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing transformative therapies.
EIT Pharma has raised $35.0M across 1 funding round on record, the most recent a Series A of $35.0M announced in Aug 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
EIT Pharma Company Profile and Key Stats
Latest funding round on record: Aug 2026.
EIT Pharma Funding Rounds
EIT Pharma Investors
EIT Pharma Funding Compared to Other Biotechnology Startups
EIT Pharma's latest round of $35.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like EIT Pharma in Biotechnology and Kirkland
Companies Similar to EIT Pharma
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
EIT Pharma Funding FAQs
What does EIT Pharma do?
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing transformative therapies.
How much funding has EIT Pharma raised?
EIT Pharma has raised $35.0M across 1 round on record. The most recent is a Series A of $35.0M announced in Aug 2026.
When did EIT Pharma last raise funding?
EIT Pharma's most recent funding round on record is a Series A of $35.0M, announced in Aug 2026.
Who has invested in EIT Pharma?
Investors on record for EIT Pharma include Arrowtown, Propel Bio Partners, Good Ventures.
Where is EIT Pharma headquartered?
EIT Pharma is based in Kirkland, United States.
How many employees does EIT Pharma have?
EIT Pharma is in the 1-10 employee band.
How does EIT Pharma's funding compare to other Biotechnology startups?
EIT Pharma's latest round of $35.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's EIT Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for EIT Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.